Jeremy Mark Pantin MD FACP
Hematologic Oncology
Clinical Director, Adult Services. Sarah Cannon Transplant and Cellular Therapy Program, Nashville
Join to View Full Profile
2410 Patterson StSuite 500Nashville, TN 37203
Phone+1 615-342-3385
Dr. Pantin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jeremy Pantin is a hematologist in Nashville, TN and is affiliated with TriStar Centennial Medical Center. He received his medical degree from University of the West Indies Faculty of Medicine and has been in practice 22 years. He specializes in hematologic oncology and is experienced in transplant and cellular therapy.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Howard UniversityResidency, Internal Medicine, 2004 - 2007
University of the West Indies Faculty of MedicineClass of 1997
Certifications & Licensure
KY State Medical License 2019 - 2026
TN State Medical License 2018 - 2026
GA State Medical License 2011 - 2025
MD State Medical License 2007 - 2025
DC State Medical License 2004 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
- A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Start of enrollment: 2022 Feb 21
- NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Start of enrollment: 2020 Sep 21
Publications & Presentations
PubMed
- Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.Uttam K Rao, Navneet S Majhail, Betsy Blunk, Karin Abernathy, Carlos Bachier
Transplantation and Cellular Therapy. 2025-03-21 - Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.Melissa Alsina, Binod Dhakal, Jeremy Pantin, Carol A Huff, Murali Janakiram
Future Oncology. 2025-03-18 - 1 citationsAccess barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.Minoo Battiwalla, Michael Tees, Ian Flinn, Jeremy Pantin, Jesus Berdeja
Blood Advances. 2025-01-28
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
- Standardization of Outpatient Care After CAR-T Therapy Across a Large Cell Therapy Network- Through Technology and Decentralized Virtual Nurses: Preliminary ResultsDecember 2023
Press Mentions
- NMDP/Be the Match Announces the Launch of Be the Match BioBank Cryopreservation ServiceNovember 5th, 2020
Professional Memberships
- Member
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
